22:44 , May 22, 2019 |  BC Extra  |  Clinical News

May 22 Clinical Quick Takes: Lilly's mirikizumab meets Crohn's endpoints; plus Novartis, 89bio and more

Lilly's mirikizumab meets in Phase II for Crohn’s  Mirikizumab (LY3074828) from Eli Lilly and Co. (NYSE:LLY) met the primary and secondary endpoints of improving clinical and endoscopic measures of disease activity at week 12 vs....
20:44 , May 22, 2019 |  BC Extra  |  Company News

May 22 Company Quick Takes: Lilly adds warning to Verzenio's Japanese label; plus Janssen, a pair of China approvals and more

Lung disease warning for Lilly breast cancer drug in Japan  Eli Lilly and Co. (NYSE:LLY) told BioCentury it has updated the Japanese label of breast cancer drug Verzenio abemaciclib to include a warning for interstitial...
19:24 , May 17, 2019 |  BioCentury  |  Product Development

Pushing China to the forefront: When a first-in-China regulatory strategy makes sense

As reforms in China shorten clinical and regulatory timelines for biotechs across the board, the country has a growing chance to become the first stop for regulatory approvals of first-in-class drugs. The decision to do...
23:10 , May 16, 2019 |  BC Extra  |  Clinical News

Roche, Bayer unveil brain tumor data for NTRK inhibitors ahead of ASCO

Efficacy data for two tissue-agnostic NTRK inhibitors from Roche and Bayer to treat primary and metastatic brain tumors were released in abstracts ahead of the American Society of Clinical Oncology meeting in Chicago. Data from...
19:53 , May 13, 2019 |  BC Extra  |  Company News

May 13 Company Quick Takes: PeptiDream/JCR, Grail, Lilly, Onconova/HanX, Regeneron

PeptiDream, JCR deal produces drug carriers for CNS delivery  The 2016 partnership between PeptiDream Inc. (Tokyo:4587) and JCR Pharmaceuticals Co. Ltd. (Tokyo:4552) has led to the development of constrained peptides that bind TFRC and are...
19:25 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

PARG inhibition for ovarian cancer

DISEASE CATEGORY: Cancer INDICATION: Ovarian cancer Cell culture experiments suggest inhibiting PARG alone or in combination with Chk1 inhibitors could help treat ovarian cancer. In three human ovarian cancer cell lines, a tool compound PARG...
01:42 , May 4, 2019 |  BioCentury  |  Product Development

How the amyloid hypothesis holds its grip

By now, two things are clear about the amyloid hypothesis of Alzheimer’s disease: one is that the amyloid peptide is somehow involved; the other is that it’s a terrible target. β amyloid has had an...
01:39 , May 4, 2019 |  BioCentury  |  Product Development

Amyloid: how did we get here and what can we learn?

Unlike any other theory in drug development, the amyloid hypothesis of Alzheimer’s disease has maintained an almost cult-like following, despite two decades littered with a long line of late-stage failures and not a single success....
00:21 , May 3, 2019 |  BC Innovations  |  Product Development

With a deal and a debut, targeted oligo delivery gets a boost from ADCs

The marriage of antibody-drug conjugates and oligonucleotides won two votes of confidence last month with a deal between Lilly and Avidity, and the debut of Atlas-backed Dyne Therapeutics. The approach promises delivery of oligos to...
23:05 , May 2, 2019 |  BC Innovations  |  Translation in Brief

Public funding highlights

Public funding highlights Selected developments and initiatives in 1Q19 from major sources of public funding including National Institutes of Health (NIH), the U.K.’s Medical Research Council (MRC), the Innovative Medicines Initiative (IMI), the Canadian Institutes...